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INTRODUCTION
S
ite-directed spin-labeling is typically accomplished
by producing a single-Cys mutant of a protein and
then labeling with a thiol-specific spin label. The
electron paramagnetic resonance (EPR) spectrum of
a Cys-attached spin label is sensitive to the protein’s
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secondary and tertiary structure near the labeled site, but
flexible attachment of the probe makes the data only indi-
rectly related to peptide backbone dynamics.1,2 This problem
was solved by the introduction of the paramagnetic amino
acid 2,2,6,6-tetramethylpiperidine-1-oxyl-4-amino-4-carbox-
ylic acid (TOAC), which is rigidly coupled to the -carbon
and thus reports more accurately the position, orientation,
and dynamics of the peptide backbone.3–5 Using 9-fluorenyl-
methoxycarbonyl (Fmoc) methodology,6 TOAC can be
inserted at any position in the peptide chain.7–9 Today the
technology of stepwise Fmoc solid-phase peptide synthesis
(SPPS) on a resin support is used routinely up to 50 residues
in length, and optimized automated protocols have been
described that extend target sequences to over 100 residues.10
We previously reported the synthesis of phospholamban
(PLB),11 a 52-amino-acid integral membrane protein that
regulates calcium transport in the heart.12 Although the spec-
troscopic techniques of NMR,13,14 FRET,15,16 FTIR,17 and cir-
cular dichroism (CD)18,19 have been applied effectively to
investigate PLB, spin labeling EPR has played a unique role
in defining the functional dynamics of PLB’s regulatory
interaction with sarcoplasmic reticulum calcium ATPase
(SERCA).11,13,20–22 SPPS allowed us to incorporate TOAC at
selected sites. We then reconstituted labeled PLB into lipids,
verified inhibitory function, and used EPR to determine the
nanosecond rotational dynamics and membrane topology of
four labeled sites in lipid membranes.11 Further studies with
TOAC-PLB explored changes in structural dynamics upon
phosphorylation and interaction of PLB with the regulatory
target, SERCA.13,20 However, difficulty in coupling TOAC
and subsequent amino acids has been a serious limitation of
this spin probe.23 This is mostly due to the very low nucleo-
philicity of its amine function when bound to a peptide
sequence (pKa < 6).
24,25 This problem can be overcome
when a more efficient coupling procedure is applied.9 The
synthesis and analysis of the 52 amino acid membrane pep-
tide represents an additional challenge. The hydrophobic res-
idues in the transmembrane domain of PLB can lead to steric
hindrance and inaccessibility of the free amino group to the
growing peptide chain. Side-products that build up over
many coupling steps often make purification difficult.
Because of these problems, the successful TOAC-PLB synthe-
sis was found to require further analytical optimization, with
a combination of analytical methods that can enhance qual-
ity assurance throughout the synthetic process.
The primary innovation in the present study is the use of
EPR spectroscopy to provide detailed analysis of the chemical
structure at key points in the synthetic procedure. MALDI-
TOFMS of the peptide segments was used before TOAC cou-
pling. EPR of lipid-bound synthetic intermediates was used
to monitor Fmoc-TOAC coupling and Fmoc deprotection.
CD spectroscopy was used to detect changes in secondary
structure, thus aiding in the interpretation of EPR spectra.
MATERIALS AND METHODS
Solid-Phase Peptide Synthesis of TOAC-PLB
Figure 1 shows the sequence of the PLB segment from amino acid
11–52, with the spin-labeled amino acid TOAC attached at position
11. Protocols for the PLB solid-phase peptide synthesis, deprotec-
tion, cleavage, and HPLC purification,19,26,27 9-fluorenylmethoxy-
carbonyl (Fmoc)-TOAC-OH synthesis,5,9 and TOAC attachment at
position 11 on PLB11,20 have been reported previously. We showed
that monomeric AFA-PLB has similar inhibitory activity as wild-
type PLB, and that AFA-PLB retains inhibitory potency when Ala11
is replaced by TOAC.11 EPR spectra of TOAC at this labeling site
have been shown to be quite sensitive to functionally important
structural changes in the cytoplasmic domain of AFA-PLB.20
Liposome Preparation
DOPC and DOPE phospholipids were obtained from Avanti Polar
Lipids. Lipids were dissolved in chloroform and peptide in metha-
nol. These solutions were mixed, with a molar ratio of 200 lipids per
peptide, in a glass tube and dried under a low flow of nitrogen to
form a thin film. Residual solvent was removed under vacuum for
several hours. The resulting lipid film was hydrated with an appro-
priate volume of 10 mM Tris (pH 7.0), to yield a final lipid concen-
tration of 8–10 mM, and vortexed to produce lipid vesicles. Vesicle
suspensions for circular dichroism (CD) experiments were soni-
cated 20 min or more in a bath sonicator. This process produced
clear solutions that scattered light only minimally in the 190–
250 nm wavelength range used for CD.
CD
CD spectra were recorded on a Jasco J-710 spectrophotometer at
258C using a 0.01 cm path-length quartz cuvette. Acquisition was
performed using a 50 nm/min scan rate, 1 nm bandwidth, and 2 s
filter time constant. The corresponding baseline (buffer or lipid/
buffer solution) was subtracted from each spectrum. Each reported
spectrum is the average of six scans, expressed as mean residue ellip-
ticity, []. Aqueous solutions for CD were prepared by drying a vol-
ume of peptide stock solution (*3 mg/ml in chloroform or metha-
nol) under a low flow of N2 and adding the appropriate amount of
10 mM Tris (pH 7.0) to give final peptide concentrations of 0.1–
0.5 mM. CD basis spectra corresponding to pure -helix, -sheet,
or random coil were obtained from standard samples of poly(lysine)
and poly(glutamic acid) (Sigma), using conditions and parameters
reported previously.28,29 Each spectrum was fit by a linear combina-
tion of these basis spectra to determine the mole fraction of amino
acids contributing to each type of secondary structure.19
FIGURE 1 Amino acid sequence from 11 to 52 of AFA-PLB.
TOAC (t) is substituted for Ala at position 11.
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MALDI-TOF-MS
Mass spectral data was acquired with a Bruker Biflex III Matrix-
Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-
TOF) system, which is equipped with an N2-laser (337 nm, 3-nano-
second pulse length) and a microchannel plate detector. The data
was collected in the linear mode, positive polarity, with an accelerat-
ing potential of 19 kV. Each spectrum is the accumulation of 100–
400 laser shots. The samples were cocrystallized with the matrix 3,5-
dimethoxy-4-hydroxycinnamic acid (sinapinic acid).
EPR Spectroscopy
For EPR experiments, PLB was reconstituted into lipid vesicles con-
taining DOPC/DOPE (4:1, 200 lipids per PLB) in 25 mM imidazole
(pH 7.0).11 Scan width 120-G spectra were acquired using a Bruker
EleXsys 500 spectrometer equipped with the SHQ cavity, using
100 kHz field modulation with peak-to-peak amplitude of 3.0 G
and microwave power of 12.6 mW, corresponding approximately to
the maximum signal.11,20 A typical sample contained 5 l of 0.5 mM
PLB, loaded into a 25 l Wiretrol (Drummond Scientific Com-
pany). Sample temperature was maintained at 48C using the Bruker
temperature controller, with the sample cell inside a quartz Dewar.
Protein Sequencing
N-terminal amino acid sequencing on resin-bound full-length crude
PLB was performed by automated Edman sequencing using an
Applied Biosystems 494HT sequencer equipped with a 610A data
analysis module (version 2.1). All operations were carried out as
prescribed in the Applied Biosystems sequencer manual.
RESULTS
The combined analytical approach was carried out as follows:
(1) preliminary analysis of the crude PLB12-52 segment by
MALDI/TOFMS, (2) EPR to monitor Fmoc TOAC coupling
and Fmoc deprotection, (3) CD of the purified PLB segments
to determine secondary structural composition, and (4)
Edman sequencing to confirm the final PLB sequence.
Analysis by MALDI/TOFMS
MALDI/TOFMS of the crude PLB segment synthesized from
amino acid 12–52 confirmed its high purity. The mass spec-
trum (Figure 2) shows the presence of one main peak corre-
sponding to m/z value of 4767.6 [M + H]+, which is in agree-
ment with the theoretical value of the PLB12-52 segment of
4766.8 Da. The minor peak at an m/z value of 4654.5 [M +
H]+ indicates the presence of impurity, which could be
ascribed to the deletion of one leucine or isoleucine. The
purity was increased after HPLC purification, and no N-
Fmoc-terminated peptides were detected by mass spectros-
copy.
Detection of Peptide Dynamics by EPR
The Fmoc group (structure in Figure 3, top, right) is the
most widely used group in urethane-type protection.6,30,31
The geometry of the Fmoc group is rigid, with the fluorenyl
ring unchanged with respect to the unsubstituted fluorene
molecule.32 Coupling such N-protected amino acids with
other amino acids or peptides proceeds without racemiza-
tion, whatever activation method is employed.33 Side chain
protection of Fmoc amino acids that can undergo irreversible
side reactions during SPPS require blocking groups that are
ideally base stable and TFA labile.34 For PLB synthesis, the
acidolyzable side chain protecting groups have been recently
published.27 Serine has been protected by a tBu side chain to
avoid active ester coupling of unprotected FmocSer during
SPPS. Similarly, to prevent acetylation of Arg, it was pro-
tected by a Pmc side chain.34 The aim of these experiments
was to use EPR to monitor structural changes that occur dur-
ing Fmoc coupling and deprotection in the synthesis of
TOAC-spin-labeled PLB. Samples for EPR were obtained af-
ter the final cleavage from the resin with TFA, which also
removes the side chain protecting groups. Then each crude
PLB segment was reconstituted in lipid bilayers, and the EPR
spectrum was recorded. Thus in the pairs of spectra in Figure
3, the only difference is whether the Fmoc group remains on
the N terminus.
Figure 3 shows EPR spectra upon the coupling of Fmoc-
TOAC at position 11 on PLB, followed by Fmoc deprotection
and subsequent steps in the peptide chain assembly from
position 11–9. In each case, the removal of the Fmoc group
(deprotection) greatly increases the mobility of the TOAC
FIGURE 2 Positive-mode linear MALDI mass spectrum of crude
PLB segment 12–52.
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spin label at position 11 (see Figure 3), i.e., each ‘‘+Fmoc’’
spectrum contains a larger contribution from peak T (corre-
sponding to an ordered -helical conformation of the pep-
tide backbone) than its corresponding deprotected
(‘‘Fmoc’’) spectrum. In particular, Fmoc deprotection of
TOAC 11 almost completely eliminates the ordered popula-
tion T (Figure 3A, bottom), in favor of the dynamically dis-
ordered population that gives rise to peak R.
The subsequent coupling of FmocSer at position 10 has an
equally significant effect in the opposite direction, completely
immobilizing the spin label at TOAC 11, so that only the T
population is observed (Figure 3B, top). This pattern continues,
in less significant fashion, for the next Fmoc protected amino
acid (Arg 9), as the peptide synthesis continues (Figure 3C).
The hydrophobic nature of the attached Fmoc group
probably interacts with the hydrophobic phase of the lipid
bilayer, inducing a more stable helix within this N-terminal
region, which causes the restriction in nanosecond dynamics.
CD
To more fully characterize the PLB system, we used CD spec-
troscopy to measure the secondary structure of the PLB seg-
ments studied by EPR Figure 3. The CD spectrum of Fmoc-
PLB12-52 mixed with DOPC/DOPE (50:1) lipids shows the
characteristic -helical negative maxima at 207 and 222 nm
and positive maximum at 193 nm (Figure 4, red). The linear
fit of the spectrum (CD data analysis reported in Material
and Methods section) yielded 85–90% helix. After Fmoc-
deprotection (Figure 4, black), the spectrum differs substan-
tially, suggesting a partial loss of -helical structure. This
supports the hypothesis that the Fmoc group stabilizes the
helix within the N-terminal region of the peptide, because of
its interaction with the lipid bilayer membrane. This struc-
tural enhancement could arise from interpeptide interac-
tions19 or interactions between the fluorenyl groups.35
Protein Sequencing
Automated Edman sequencing (see Figure 5) was used to
confirm the primary structure of the completed peptide 11-
TOAC-AFA-PLB (sequence of full-length AFA-PLB Figure 6,
top). Although mass spectrometry is an efficient method for
determining peptide sequence, it has limitations. The inser-
tion of unnatural amino acids or free radicals generates am-
biguity. Furthermore, MS analysis requires the additional
FIGURE 3 EPR spectra of sequential synthetic intermediates in lipid bilayers. Each pair of spec-
tra was obtained before and after Fmoc removal; (A) PLB12-52 after coupling of FmocTOAC at
position 11, (B) after subsequent coupling of FmocSer at position 10, and (C) after subsequent cou-
pling of FmocArg at position 9. Spectra were normalized to unit concentration by dividing by the
double integral. Scan width 120-G.
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steps of peptide cleavage and extraction from the resin.
Edman degradation sequence analysis can be used for evalu-
ating the synthesis for resin-bound peptides.36 Edman chem-
istry converts each -amino acid sequentially to its PTH de-
rivative. The formed PTH amino acids can be identified by
their retention times on HPLC by comparison with reference
standards. Since the by-product DPTU appears on each
amino acid residue cycle during the process of sequencing,
this peak can be used as excellent internal reference peak.37
Edman sequencing of peptides containing unnatural amino
acids was previously reported,37 but there is no literature on
the sequencing of TOAC peptides. We used automated
Edman sequencing to confirm the final 10 amino acids after
TOAC coupling at position 11. Figure 5A shows the chroma-
tography of the standard mixture of the 19 PTH amino acids
used as reference for the amino acid assignment. Figures 5B–
5D shows the HPLC elution profile of the first identified
amino acid Met 1, as well as the last two Arg 9 and Ser 10.
The sequence analysis confirmed the successful synthesis of
the full-length AFA-PLB with TOAC inserted at position 11.
Accessibility to the Membrane Surface
To verify the interaction of the Fmoc group with the lipid
membrane, EPR experiments were performed on full-length
AFA-PLB (Figure 6, top) with TOAC attached to the N ter-
minus. The EPR spectra (Figure 6, left) show that the Fmoc
group stabilizes the restricted (‘‘T’’) component, just as it
does in the intermediate segment PLB11-52. Power satura-
tion was used to measure the accessibility of the spin label to
Ni2+ ions chelated to the lipid headgroup. Figure 6, right
shows that accessibility of the spin-labeled peptide to the
membrane surface was higher before the removal of Fmoc
(black) than after (grey), confirming that the Fmoc group
anchors the N-terminus to the lipid bilayer.
DISCUSSION
In solid-phase peptide synthesis, Fmoc has become the most
frequently used protecting group.6,38 Its utility for the syn-
thesis of wide varieties of peptide conjugates, including
Fmoc-TOAC derivatives of membrane proteins, has been
reported.11,20 In the present study, EPR of lipid-bound syn-
thetic intermediates was applied to monitor Fmoc-TOAC
coupling and deprotection. The EPR spectra in Figure 3
clearly show that Fmoc deprotection increases TOAC mobil-
ity, and coupling of the next Fmoc amino acid decreases
FIGURE 4 CD spectra of Fmoc protected PLB12-52 (red) and af-
ter Fmoc deprotection in DOPC/DOPE mixture (50:1 lipid:peptide)
10 mM Tris, pH 7.0, 258C.
FIGURE 5 Elution profiles of 19 PTH amino acids (A), Met 1
(B), Arg 9 (C), and Ser 10 (D).
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TOAC mobility. Most importantly, the high resolution of
EPR provides quantitative measurement of the efficiencies of
several of the steps. Note that the R component of the EPR
spectrum has negligible intensity before deprotection, and
the T component has negligible intensity after deprotection
(Figure 3A). This shows clearly that the efficiency of depro-
tection is essentially 100% and that anything less than 100%
deprotection would be detected quantitatively as a peak at
the T position. Similarly, in the next step, the coupling of
FmocSer to position 10, the R component is completely elim-
inated showing that this step has gone to completion as well.
Thus, anything less than 100% coupling at this step would be
detected quantitatively as a peak at the R position. In the
subsequent steps, the spectral changes are not so extreme, so
the EPR spectra do not provide such a quantitative monitor
of the reaction.
The EPR spectra correlated well with conformational
changes obtained by CD. The observed decrease in the or-
dered T component in EPR upon deprotection (Figure 3A)
corresponds to a decrease in -helical content (see Figure 4).
EPR data in Figure 6 confirms that the rigid hydrophobic
Fmoc group anchors the cytoplasmic domain to the lipid
bilayer membrane by hydrophobic interactions and stabilizes
the helical structure. These results are consistent with a previ-
ous study in which a lipid group attached to the N terminus
of PLB increased the interaction of the N-terminal domain
of PLB with the lipid surface and increased helical order in
this domain.20 Crystal structural studies of Fmoc derivatives
suggest that its amide CONH and the urethane C¼O
group interact with the solvent molecules and stabilize the
helix.33 Previous structure–activity investigations on angio-
tensin analogs containing the bulky, lipophilic substituent
Fmoc at the N-terminus induce tachyphylaxis, defined as the
acute loss of response of some smooth muscles. The Fmoc af-
finity for the lipid membrane induces structural changes in
the peptide.39
In conclusion, the results show that the application of
conventional analytical methods in combination with EPR
offers an improved approach to optimize the accurate syn-
thesis of spin-labeled membrane peptides. The EPR studies
in lipids show that the attachment of Fmoc-TOAC leads to
strong immobilization, whereas Fmoc deprotection mobilizes
the probe. CD data confirm the conformational changes:
Fmoc induces a more stable helix within this N-terminal
region of the peptide by hydrophobic interaction with the
membrane surface. EPR is of great value in monitoring cou-
pling and deprotection steps during solid phase peptide syn-
thesis of membrane peptides since it provides relevant infor-
mation about conformational changes induced by the Fmoc
group. This approach is applicable to a large number of small
membrane proteins that, like PLB, have transmembrane heli-
ces coupled to short cytoplasmic regulatory domains, such as
sarcolipin40 and the FXYD family of plasma membrane regu-
lators.41
FIGURE 6 EPR spectra showing that the Fmoc group increases interaction of the PLB N-termi-
nus with the lipid bilayer. Top: Sequence of full-length AFA-PLB with TOAC (t) attached at the N-
terminus. Left: EPR spectra of N-terminal Fmoc-TOAC-AFA-PLB, reconstituted into lipid bilayers,
before (+Fmoc) and after (Fmoc) deprotection. Spectra were normalized to unit concentration
by dividing by the double integral. Scan width 120-G at 48C. Right: Accessibility to the membrane
surface of TOAC before (black) and after (grey) Fmoc deprotection. The accessibility (normalized
to 1 for +Fmoc) was measured as the increase in microwave power needed to for half-saturation of
the EPR signal, upon addition of Ni2+ chelated to lipid head groups, as described previously.11
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